Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Akers Biosciences (AKR)

  Print      Mail a friend

Thursday 12 April, 2018

Akers Biosciences

Independent Sales Representative Agreements - PIFA

RNS Number : 7092K
Akers Biosciences, Inc.
12 April 2018

April 12, 2018


Akers Biosciences, Inc.


Akers Bio Expands Outsourced US Distribution Capabilities for Heparin PF4 Rapid Test


Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"), a developer of rapid health information technologies, announces the engagement of two leading Independent Sales Representative (ISR) organizations to increase US sales and marketing capabilities for the Company's rapid test for heparin-induced thrombocytopenia (HIT).


The agreements with Opto-Systems, Inc. ("Opto-Systems") and Herzog Surgical, Inc. ("Herzog Surgical") are in line with Akers Bio's strategy to create platelet factor 4 awareness amongst surgeons - principally orthopaedic and cardiac surgeons - and to expand the utilization of the Company's point-of-care PIFA Heparin/PF4 Rapid Assay product platform.


Opto-Systems, based in Newtown, PA, has a 39-year history in medical device sales and distribution, with expertise in surgical specialties, including orthopaedic surgeons. Opto-Systems has a team of highly trained representatives based in Delaware, New Jersey, New York, and Pennsylvania, calling on physicians, hospitals and medical offices. Following a period of training in the sales and associated support for PIFA Heparin/PF4 Rapid Assay products, Opto-Systems will broaden Akers Bio's US sales coverage in the northeast with a specific focus on the clinical end-users of the Company's rapid test.


Herzog Surgical, based in Sacramento, CA, has a 30-year track record serving the healthcare community as a distributor of specialized products with applications in all areas of medicine. Herzog Surgical's sales team members have on average over 13 years of tenure. They bring significant relationships with cardiac surgeons as well as with hospitals and Integrated Delivery Networks within California and northern Nevada. Following a period of training in the sales and associated support for PIFA Heparin/PF4 Rapid Assay products, Herzog Surgical will broaden Akers Bio's US sales coverage across northern Nevada and the entire state of California, also with a specific focus on the clinical end-users of the Company's rapid test.


John J. Gormally, Chief Executive Officer of Akers Bio, commented: "The development of Akers Bio's Independent Sales Representative organization is a key component of our strategy to increase awareness and sales of PIFA Heparin/PF4 Rapid Assay products in the US. It represents the third wave of our commercialization strategy which included value captured in price, a strategy to target Integrated Delivery Networks and now, a strategy to influence the clinical pathway by educating the clinical end-users on the critical medical benefits of adopting this rapid test for heparin platelet factor 4 antibodies.


"We are thrilled to be working with Opto-Systems and Herzog Surgical whose respective specialized capabilities will bolster our sales efforts and allow our test to gain substantial additional regional coverage at a clinical level. We are looking forward to working with them - and other ISR organizations with whom we expect to engage in due course - to effect real change in the clinical pathway for the diagnosis of HIT."



About Akers Biosciences, Inc.


Akers Bio develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.


Additional information on the Company and its products can be found at Follow us on Twitter @AkersBio.



Cautionary Statement Regarding Forward Looking Statements


Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.


For more information:


Akers Biosciences, Inc.

John J. Gormally, Chief Executive Officer

Tel. +1 856 848 8698


finnCap (UK Nominated Adviser and Broker)

Adrian Hargrave / Scott Mathieson (Corporate Finance)

Steve Norcross (Broking)

Tel. +44 (0)20 7220 0500


Vigo Communications (Global Public Relations)

Ben Simons / Fiona Henson

Tel. +44 (0)20 7830 9700

Email: [email protected]

This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t